Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide

Carfilzomib-lenalidomide-dexamethasone (KRd) therapy has yielded promising results in patients with newly diagnosed multiple myeloma (NDMM). Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Phoebe A., Beedie, Shaunna L., Chau, Cindy H., Venzon, David J., Gere, Sheryl, Kazandjian, Dickran, Korde, Neha, Mailankody, Sham, Landgren, Ola, Figg, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795854/
https://www.ncbi.nlm.nih.gov/pubmed/31619706
http://dx.doi.org/10.1038/s41598-019-51446-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795854/
https://www.ncbi.nlm.nih.gov/pubmed/31619706
http://dx.doi.org/10.1038/s41598-019-51446-9

Ejemplares similares